Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.

The company’s stock traded at approximately $99.20 per share 10 years ago. If you had invested $10,000, you could have bought roughly 101 shares. Currently, shares trade at $155.91, meaning your investment’s value could have grown to $15,717 from stock price appreciation alone. However, Johnson & Johnson also paid dividends during these 10 years.

Don’t Miss:

• Deloitte’s fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!

• Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.

Johnson & Johnson’s dividend yield is currently 3.34%. Over the last 10 years, it has paid about $41.48 in dividends per share, which means you could have made $4,181 from dividends alone.

Summing up $15,717 and $4,181, we end up with the final value of your investment, which is $19,898. This is how much you could have made if you had invested $10,000 in Johnson & Johnson stock 10 years ago. This means a total return of 98.98%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 215.80%.

Johnson & Johnson has a consensus rating of “Buy” and a price target of $170.89 based on the ratings of 19 analysts. The price target implies a nearly 10% potential upside from the current stock price.

On April 15, the company announced its Q1 2025 earnings, posting adjusted EPS of $2.77, up 2.2% year-over-year, and above the consensus of $2.60, as reported by Benzinga.

The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year-over-year, and beating the consensus estimate of $21.58 billion.

Trending: Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — Here’s How You Can Invest in the Entertainment Market’s Next Big Disruptor for Just $998

Johnson & Johnson expects full-year 2025 sales in the range of $91 billion to $91.8 billion, compared to the prior guidance of $90.9 billion to $91.7 billion, and above the consensus of $90.62 billion.

The Medtech giant expects 2025 adjusted operational EPS to be between $10.50 and $10.70, compared to prior guidance of $10.75 to $10.95.